Effect of amidine derivatives on nitric oxide production by Leishmania amazonensis promastigotes and axenic amastigotes

Nitric Oxide - Biology and Chemistry

Volumn 8, Issue 1, 2003, Pages 1-6

  Genestra, Marcelo ^a   Echevarria, Aurea ^b   Cysne Finkelstein, Léa ^a   Vignólio Alves, Luciana ^a   Leon, Leonor L ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Leishmania amazonensis; Methoxyamidine; Nitric oxide; Nitric oxide synthase; Pentamidine

Indexed keywords

AMIDINE; ARGININE; BENZAMIDINE DERIVATIVE; N,N' DIPHENYL 4 METHOXYBENZAMIDINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PENTAMIDINE; PENTAMIDINE ISETHIONATE; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; LEISHMANIA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SUPERNATANT;

AMIDINES; ANIMALS; LEISHMANIA MEXICANA; LEISHMANIASIS; MOLECULAR STRUCTURE; NITRIC OXIDE; PENTAMIDINE;

LEISHMANIA AMAZONENSIS;

EID: 0037331658     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-8603(02)00129-5     Document Type: Article

References (56)

1. F. Modabber, Leishmaniasis in the New Word WHO Tropical Disease Research Progress 1991-1992 Program Report, (1992) 77-81.
2. Berman J.D. Chemotherapy for Leishmaniasis: biochemical mechanisms, clinical efficacy and future strategies. Rev. Infect. Dis. 10:1988;560-586.
3. Cook G.C. Leishmaniasis: some recent developments in chemotherapy. J. Antimicrob. Chemother. 31:1993;327-330.
4. Peters B.S., Fish D., Golden R., Evans D.A., Bryceson A.D., Piching A.J. Visceral leishmaniasis in HIV infection and AIDS: clinical features and reponse to therapy. Q. J. Med. 77:1990;1101-1111.
5. Grögl M., Thomason T.N., Franke E. Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:1992;117-126.
6. Endicott J.A., Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu. Rev. Microbiol. 58:1989;137-171.
7. Ouellette M., Papadopoulou B. Mechanisms of drug resistance in Leishmania. Parasitol. Today. 9:1993;150-153.
8. Goa K.L., Campoli-Richards D.M. Pentamidine isethionate: a review of its antiprotozoal activity, phamacokinetic properties and therapeutic use in Pneumocystis carinii pneumonia. Drugs. 33:1987;242-258.
9. Soto-Mancipe J., Grogi M., Berman J.D. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colômbia. Clin. Infect. Dis. 16:1993;417-425.
10. Soto J., Buffet P., Grogi M., Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg. 50:1994;105-111.
11. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:1992;3051-3064.
12. Nathan C., Xie Q-W. Nitric oxide synthases: roles, tolls and controls. Cell. 78:1994;915-918.
13. Bredt D.S., Snyder S.H. Nitric oxide: a physiologic messenger molecule. Annu. Rev. Biochem. 63:1994;175-195.
14. Garthwaite J., Boulton C.L. Nitric oxide signaling in the central nervous system. Annu. Rev. Physiol. 57:1995;683-706.
15. Augusto O., Linares E., Giorgio S. Possible roles of nitric oxide and peroxynitrite in murine leishmaniasis. Braz. J. Med. Biol. Res. 29:1996;853-862.
16. Evans A.T., Croft S.L., Peter W., Neal R.A. Antileishmanial effects of clofazimine and other antimycobacterial agents. Ann. Trop. Med. Parasitol. 83:1989;447-454.
17. S. Giorgio, E. Linares, M.L. Capurro, A.G. Bianchi, O. Augusto, Formation of nitrosyl hemoglobin and nitrotyrosine during murine leishmaniasis. Photochem. Photobiol. 63 (1996) 750-754.
18. Bories C., Scherman E., Bories P.N. Serum and tissue nitrate levels in murine visceral leishmaniasis correlate with parasite load but not with host protection. Trans. R. Soc. Trop. Med. Hyg. 91:1997;433-436.
19. L. Fonseca-Geigel, A via do óxido nítrico em Leishmania amazonensis. M.Sci. thesis. Fundação Oswaldo Cruz, Brazil.
20. Basu N.K., Kole L., Ghosh A., Das P.K. Isolation of a nitric oxide synthase from protozoan parasite, Leishmania donovani. FEMS Microb. Lett. 156:1997;43-47.
21. Cysne-Finkelstein L., Aguiar-Alves F., Temporal R.M., Leon L.L. Leishmania amazonensis: long-term cultivation of axenic amastigotes is associated to metacycligenesis of promastigotes. Exp. Parasitol. 89:1998;58-62.
22. ′ -diphenylbenzamidines Bioorg. Med. Chem. Lett. 6:1996;1901-1904.
23. Canto-Cavalheiro M., Echevarria A., Araújo C.A.C., Cysne-Finlkestein L., Leon L.L. The potential effects of new synthetic drugs against Leishmania amazonensis and Trypanosoma cruzi. Microbios. 90:1997;51-54.
24. Canto-Cavalheiro M., Echevarria A., Souza M.A.S., Cysne-Finlkestein L., Torres M.A.D., Leon L.L. Effect of amidine derivatives on Leishmania amazonensis axenic amastigotes. Arzneim. Drug Res. 50(II):2000;925-928.
25. 15nitrate in biological fluids. Anal. Biochem. 126:1982;131.
26. Tidwell R.R., Jones S.K., Gertz J.D., Ohemeng K.A., Bell C.A., Berger B.J., Hall J.E. Development of pentamidine analogues as new agents for treatment of Pneumocystis carinii pneumonia. Ann. N. Y. Acad. Sci. 616:1990;421-441.
27. Bell C.A., Hall J.E., Kyle D.E., Grogl M., Ohemeng K.A., Allen M.A., Tidwell R.R. Structure-activity relationships of analogs of Pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. J. Antimicrob. Chemother. 34:1990;449-461.
28. Anonymous Pentamidine isethionate approved for Pnemocystis carinii pneumonia. FDA Drug. Bull. 14:1984;25-26.
29. Pearson P.D., Hewlett E.L. Pentamidine for the treatment of Pneumocystis carinii pneumonia and other protozoan diseases. Ann. Intern. Med. 103:1985;782-786.
30. Basselin M., Lawrence F., Robert-Gero M. Pentamidine uptake in Leishmania donovani and L. amazonensis promastigotes. Biochem. J. 315:1996;631-634.
31. Ephros M., Bitnun A., Shaked P. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob. Agents Chemother. 43:1999;278-282.
32. Sereno D., Lemesre J.L. In vitro life cycle of Pentamidine-resistant amastigotes. Stability of chemoresistant phenotypes is dependent on the level of resistance induced. Antimicrob. Agents Chemother. 41:1997;1898-1902.
33. Sereno D., Lemesre J.L. Axenically cultured amastigotes forms as an in vitro model for investigation of antileishmanial agents. Antimicrob. Agents Chemother. 4:1997;972-976.
34. Sereno D., Cavaleyra M., Zemzouni K., Maquaire S., Quaissi A., Lemesre J.L. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob. Agents Chemother. 42:1998;3097-3102.
35. Callahan H.L., Portal A.C., Devereaux R. An axenic amastigote system for drug screening. Antimicrob. Agents Chemother. 41:1997;1-5.
36. Johnson R., Cubría J.C., Reguera R.M., Balaña-Fouce R., Ordóñes D. Interaction of cationic diamidines with Leishmania infantum DNA. Biol. Chem. 379:1998;925-930.
37. Gomes-Cardoso L., Echevarria A., Aguiar-Alves F., Jansen A.M., Leon L.L. Comparative analysis of the efficiency of amidine derivatives on different isolates of Trypanosoma evansi. Mem. Inst. Oswaldo Cruz. 93:1998;297.
38. Liew F.Y., Wei X., Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos. Trans. R. Soc. London. 352:1997;1311-1315.
39. Green S.J., Meltzer M.S., Hobbs J.B., Nacy C.A. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144:1990;278-283.
40. Sands M., Kron M.A., Brown R.N. Pentamidine: a review. Rev. Infect. Dis. 6:1985;625-634.
41. Banerjee G., Nandi G., Mahato B., Pakrshi A., Basu M.K. Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes. J. Antimicrob. Chemother. 38:1996;145-150.
42. Basselin M., Lawrence F., Robert-Gero M. Pentamidine uptake in Leishmania donovani and L. amazonensis promastigotes. Biochem. J. 315:1996;631-634.
43. Pearl L.H., Skelly J.V., Hudson B.D., Neidle S. The crystal structure of DNA-binding drug Berenil: a molecular modeling of Berenil-DNA complex. Nucleic Acids Res. 15:1987;3469-3478.
44. Basu H.S., Marton L.J. The interaction of spermine and pentamidines with DNA. Biochem. J. 35:1987;43-50.
45. Kandpal M., Fouce R.B., Pal A., Guru P.Y., Tekwani B.L. Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 71:1995;193-201.
46. Camargo E.P., Coelho J.A., Figueiredo E.N. Trypanosoma spp, Leishmania spp and Leptomonas spp. Enzymes of ornithine-arginine metabolism. Exp. Parasitol. 46:1978;141-144.
47. Genestra M., Echevarria A., Cysne-Finkelstein L., Leon L.L. Protein kinase A of Leishmania amazonensis as a potential target for methoxy-amidine. Arzneim. Drug Res. 51(II):2001;920-923.
48. ′ -difenilbenzamidinas: síntese, correlações de Hammet e atividade biológica. M.Sci. thesis. Instituto de Ciências Exatas. UFRRJ.
49. Balestieri F.M.P., Queiroz A.R.P., Scavone C., Costa V.M.A., Barral-Netto M., Abrahamsohn I.A. Leishmania (L.) amazonensis-induced inhibition of nitric oxide synthesis in host macrophages. Microbes Infect. 4:2002;23-29.
50. Proudfoot L., O'Donnll C.A., Liew F.Y. Glycoinositolphospholipids of Leishmania major inhibit nitric oxide synthesis and reduce leishmanicidal activity in murine macrophages. Eur. J. Immunol. 25:1995;745-750.
51. Barret M.P., Fairlamb A.H. The biochemical basis of arsienical-diamidine crossresistance in African Trypanosomes. Parasitol. Res. 315:1999;631-634.
52. Coombs G.H., Craft J.A., Hart D.T. A comparative study of Leishmania mexicana amastigotes and promastigotes. Enzyme activities and subcellular locations. Mol. Biochem. Parasitol. 5:1982;199-211.
53. Hassan H.F., Coombs G.H. Leishmania mexicana: purine metabolizing enzymes of amastigotes and promastigotes. Exp. Parasitol. 59:1985;15-28.
54. Lemesre J.L., Sereno D., Daulouede S., Veyret B., Brajon N., Vincendau P. Leishmania spp: nitric oxide-mediated metabolic inhibition of promastigote and axenically-grown amastigote forms. Exp. Parasitol. 86:1997;58-68.
55. Wickelgren W. Biologists catch their first detailed look at NO enzyme. Science. 278:1997;389.
56. Smith D.A. Design of drugs trhough a consideration of drug metabolism and pharmacokinetics. Eur. J. Drug Metab. 3:1994;193-199.